⚠️ No article content returned.
Astrazeneca PLC (AZN)
- Written by: Madison Wilson
Latest Company News
AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease offset Farxiga and China headwinds. The company raised its interim dividend, secured 30 approvals, and reaffirmed full-year guidance and its $80 billion 2030 revenue goal.
Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial.
Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer.
Astrazeneca Plc has agreed an exclusive licence with Dizal Pharmaceutical for Zegfrovy, adding a novel oral EGFR inhibitor to its oncology portfolio.
The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy...
Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer.
